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Background
It has been hypothesised that the slow progression to
AIDS exhibited by HLA-B*2705+ HIV-infected individuals
is due to the immunodominant B*27-restricted response
towards the p24 Gag epitope KK10 (Gag residues 263–
272). This study aims to discern the contributing corre-
lates of immune protection in HLA-B*2705+ HIV-infected
individuals by comparing CD8+ T cell epitope specificity,
cytokine profile, granzyme production and the kinetics of
epitope presentation.
Methods
HLA-B*2705 MHC-I tetramers were used to enrich CD8+
T cell lines (>98% specific), specific for the Gag epitope
KK10, the Vpr epitope VL9, and Pol epitope KY9. We com-
pared the polyfunctionality, proliferation, granzyme pro-
duction and specific killing capacity of these epitope-
specific CD8+ T cells. We also compared the polyfunction-
ality and granzyme production of epitope-specific CD8+ T
cells directly from ex vivo PBMCs. We then compared the
ability of the different B*2705-restricted epitope specific
CD8+ T cell lines (>98% specific) to suppress viral replica-
tion in vitro. HIV-permissive cells expressing B*2705 were
infected and cocultured with the CD8+ T cells, firstly by
synchronized magnetofection™ and monitored over 24
hours and secondly by 'natural' infection and monitored
over 5–10 days.
Results
The Gag KK10- and Pol KY9-specific CD8+ T cells could
elicit antiviral activity by 6 hours post-infection whereas
the Vpr VL9-specific CD8+ T cells didn't elicit antiviral
activity until 18 hours post-infection. We observed a clear
hierarchy of antiviral potency dictated by epitope or HIV
protein specificity (Gag KK10>Pol KY9>Vpr VL9). Antivi-
ral activity did not correlate with polyfunctionality, prolif-
eration, granzyme production or killing capacity.
Conclusion
The potent antiviral activity displayed by Gag KK10-spe-
cific CD8+ T cells may be due to early presentation of Gag
epitopes on HIV-infected cells. A vaccine which promotes
CD8+ T cells which can elicit early antiviral activity may
help prevent viral dissemination during HIV infection and
is a rational approach to vaccine design.
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